WHO using ring vaccine approach against Ebola
Ring vaccination involves vaccinating anyone who came into contact with an infected patient, plus the contacts of contacts. The experimental drug being used is a VSV-EBOV vaccine currently in a Phase 3 efficacy trial.
A team from Conakry, Guinea joined a World Health Organization and Sierra Leone Ministry of Health team in Kambia to track the transmission source and locate anyone who may have come in contact with the infected patient. They were joined by another team from Freetown, South Africa.
“Although no-one wanted to see more cases of Ebola virus disease in Sierra Leone, we kept all our teams on alert and ready to respond and close down any new transmission,” Dr. Anders Nordstrom, WHO representative in Sierra Leone, said.
The vaccine trial is funded by WHO, with support from the Wellcome Trust, the United Kingdom Department for International Development, the Norwegian Ministry of Foreign Affairs to the Norwegian Institute of Public Health through the Research Council of Norway, the Canadian government through the Public Health Agency of Canada, Canadian Institutes of Health Research, International Development Research Centre and Department of Foreign Affairs, Trade and Development, and MSF.